


Pembrolizumab KEYNOTE-164

PRELIMINARY SCORE

CURATIVE



NON-CURATIVE



ADJUSTMENTS

Quality of life



Serious and disabling adverse effects




Other adjustments



Pembrolizumab KEYNOTE-164

FINAL SCORE

CURATIVE



Overall Survival / Disease-Free Survival / Pathological Complete Response

NON-CURATIVE



Overall Survival



Progression-Free Survival



Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate



Overall Response Rate / Duration of Response

Overall Survival / Disease-Free Survival / Pathological Complete Response

INFORMATION

Tumour type: Gastrointestinal Cancers  
Therapeutic Indication: Treatment of adults with MSI-H or dMMR unresectable or mCRC after previous fluoropyrimidine-based combination therapy  
Experimental Arm: Pembrolizumab  
Control Arm: Single arm

